Medicap Healthcare Limited Files DRHP With SEBI

Medicap Healthcare Limited (“The Company”) has filed its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI).

Here To Join Us On WhatsApp

The company is a prominent player in the Indian pharmaceutical packaging sector, specializing in the production of pharmaceutical closures, including Euro Head caps and bottle preforms.

As of FY2025, the company’s 80.02% Revenue from Operations is from domestic sales and balance 19.98% is from exports to 14 countries. The Company has about 1.4% of the global market share and more than 40.00% domestic market share for Euro Head caps. (Source: F&S Report).

Here To Join Us On WhatsApp

The company plans to raise fund through the Initial Public Offering. The total Issue size comprises of Fresh Issue aggregating up to ₹ 2,400 million (₹ 240 Crore) (“Total Issue Size”). There is no Offer-For-Sale component. 

The objects of the Issue are to (i) Purchase of plant and machinery for the existing Manufacturing Unit, aggregating up to ₹ 743.70 million (₹ 74.37 Crore); (ii) Repayment or pre-payment, in full or part, of certain borrowings availed by the Company, aggregating up to ₹ 329.00 million (₹ 32.90 Crore); (iii) Investment in their Subsidiary KASR Healthcare Private Limited for Repayment or pre-payment, in full or part, of certain borrowings availed by the Company, aggregating up to ₹ 528.00 million (₹ 52.80 Crore); and balance for General Corporate Purposes. (“Objects of the Offer”).

Here To Join Us On WhatsApp

Aryaman Financial Services Limited is the sole Book Running Lead Manager for the Issue.

About Company:

Medicap Healthcare Limited is a prominent player in the Indian pharmaceutical packaging sector, specializing in the production of pharmaceutical closures, including Euro Head caps and bottle preforms.

The company operate from a 6,732 sq. mt. state-of-the-art manufacturing facility, located at Manjusar, Vadodara, Gujarat, having a total annual installed capacity of manufacturing approximately 751 million units (389 million units in pharma packaging Euro Head Caps, 149 million units in bottle preforms and 213 million units in other protector caps) The company produced 454 million units in FY2025.

Here To Join Us On WhatsApp

The company’s manufacturing adheres to stringent quality standards, ensuring the safety and integrity of pharmaceutical products. The company is certified with ISO 9001:2015, ISO 14001:2015 and adheres to Good Manufacturing Practices (GMP) and Drug Master File (DMF) guidelines.

As on FY 25, the company has a pan-India presence across 21 States and 5 Union Territories and robust sales presence across 14 countries. In addition to its primary focus on Euro Head caps and preforms, Medicap has expanded its capabilities through its subsidiary, KASR Healthcare Private Limited, further strengthening its presence in the pharmaceutical and healthcare supply chain

Next Story:

Now you can get the latest stories from Indtoday on Telegram every day. Click the link to subscribe.  Click to follow Indtoday’s Facebook page, Twitter, and Instagram. For all the latest Hyderabad News updates